Ambit Biosciences Inks $30M in D-2 Round
Ambit Biosciences, a biopharmaceutical company developing kinase inhibitors for the treatment of cancer and other conditions, has inked $30 million in new capital. Apposite Capital led the Series D-2 round, which included participation from existing investors Perseus-Soros Biopharmaceutical Fund, OrbiMed Advisors, Forward Ventures, Roche Venture Fund, MedImmune Ventures, GIMV, GrowthWorks, Genechem, Radius Ventures, NovaQuest and Horizon Technology Finance. The money will help the company continue clinical development.
10 June 2011•3 mins read
